Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.

Molecular pharmacology - 1 Dec 1996

Nguyen A, Kath J C, Hanson D C, Biggers M S, Canniff P C, Donovan C B, Mather R J, Bruns M J, Rauer H, Aiyar J, Lepple-Wienhues A, Gutman G A, Grissmer S, Cahalan M D, Chandy K G

Abstract excerpt

The nonpeptide agent CP-339,818 (1-benzyl-4-pentylimino-1,4-dihydroquinoline) and two analogs (CP-393,223 and CP-394,322) that differ only with respect to the type of substituent at the N1 position, potently blocked the Kv1.3 channel in T lymphocytes. A fourth compound (CP-393,224), which has a smaller and less-lipophilic group at N1, was 100-200-fold less potent, suggesting that a large lipophilic group at this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HeLa Cells
Share to Lymphocyte Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Potassium Channel Blockers

Share to Potassium Channels

Share to Protein Conformation

Share to T-Lymphocytes

Source

Identifiers

PMID: 8967992

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.PMID 8967992Read ↗

Kv1.3 in the spotlight for treating immune diseasesSemantic proximity Read ↗

Potassium channels as therapeutic targets for autoimmune disorders.Semantic proximity Read ↗

State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.Semantic proximity Read ↗

Different residues in channel turret determining the selectivity of ADWX-1 inhibitor peptide between Kv1.1 and Kv1.3 channels.Semantic proximity Read ↗

A Novel Fluorescent Toxin to Detect and Investigate Kv1.3 Channel Up-regulation in Chronically Activated T LymphocytesSemantic proximity Read ↗

Tyrosine phosphorylation of the Kv1.3 potassium channel.Semantic proximity Read ↗

New screening system for selective blockers of voltage-gated K(+) channels using recombinant cell lines dying upon single action potential.Semantic proximity Read ↗

Large T-antigen up-regulates Kv4.3 K+ channels through Sp1, and Kv4.3 K+ channels contribute to cell apoptosis and necrosis through activation of calcium/calmodulin-dependent protein kinase IISemantic proximity Read ↗

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.Semantic proximity Read ↗

Targeted knockdown of Kv1.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosusSemantic proximity Read ↗

Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.Semantic proximity Read ↗

Characterization and molecular basis for the block of Kv1.3 channels induced by carvedilol in HEK293 cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.